Extensions¶
The extensions are the pieces that sit beyond the core mechanism: an aggregation-within-cell diagnostic, the fiscal procurement-cost implication, and the mapping from the measured mechanism to policy instruments. None of them changes the core claim; each adds context or quantifies a consequence.
Aggregation within cells¶
If lost scale is part of the cost margin, then aggregating demand within finer cells should attenuate the litigated-over-administrative gap. The aggregation-within-cell diagnostic tests this directly. The evidence is mixed: the direction is consistent with the scale channel in some cells but is not uniform, and the exercise is reported as a diagnostic rather than a clean estimate of an aggregation counterfactual.
Economic intuition
If lost scale is genuinely part of the cost, then forcibly aggregating demand within finer cells should shrink the litigated-over-administrative gap. The evidence leans that way but is noisy — which is why it is reported as a diagnostic consistent with the scale channel, not as an estimate of what an aggregation policy would actually deliver.
Detail: AN-009 — Aggregation within cells.
Fiscal procurement-cost implication¶
Applying the bounded litigated-over-administrative gap to annual litigated pharmaceutical spending in São Paulo gives a fiscal procurement-cost implication:
$27.8M / year Fiscal procurement-cost implication (Lee range \(23.9M–\)31.7M). This is a fiscal procurement-cost calculation, not a full welfare estimate: it excludes health benefits, search costs, compliance benefits, and other welfare components, and it should not be read as the value of scaling back legal enforcement.
Economic intuition
Scaling the bounded gap by admissible litigated spending gives the order of magnitude of what fragmentation costs the treasury in procurement prices — not the welfare value of enforcement. Health benefits, timely delivery, and compliance value are deliberately left out. The number answers "how much more does the state pay to source this way," not "is the right to health worth it."
Detail: AN-011 — Fiscal procurement-cost implication.
Policy instruments mapped to the mechanism¶
Because the measured margin is lost scale and supplier matching rather than contract language or price caps, the relevant instruments are those that rebuild aggregation and matching under legal urgency. Each instrument is mapped to the part of the mechanism it addresses:
| Instrument | Mechanism it addresses |
|---|---|
| Framework agreements / pooled urgent procurement | Restores scale lost to fragmented orders |
| Pre-contracted suppliers for recurring medicines | Supports supplier matching under compressed timelines |
| Stronger administrative screening | Widens an admissible no-sanction urgent route for feasible cases |
| Inventories and protocols for recurrent litigated medicines | Lets the state anticipate and aggregate demand rather than source isolated emergencies |
The paper does not estimate these tools directly. It points to them because the mechanism it measures is aggregation and supplier matching: the goal is to preserve delivery while preventing legal urgency from becoming procurement fragmentation.
Economic intuition
The instruments follow from the mechanism, not from ideology. Because the measured margin is lost scale and broken matching — not abusive contract terms or price-cap evasion — the tools that bite are those that rebuild aggregation and supplier matching under legal urgency. Capping prices would treat a symptom the data do not point to; the cause is fragmented sourcing.